Your browser doesn't support javascript.
loading
PRE-OPERATIVE GASTRIC GIST DOWNSIZING: THE IMPORTANCE OF NEOADJUVANT THERAPY.
Rodrigues, João Bernardo Sancio Rocha; Campanati, Renato Gomes; Nolasco, Francisco; Bernardes, Athos Miranda; Sanches, Soraya Rodrigues de Almeida; Savassi-Rocha, Paulo Roberto.
Afiliação
  • Rodrigues JBSR; Hospital das Clínicas, Universidade Federal de Minas Gerais, Alfa Institute of Gastroenterology, Belo Horizonte, MG, Brazil.
  • Campanati RG; Hospital das Clínicas, Universidade Federal de Minas Gerais, Alfa Institute of Gastroenterology, Belo Horizonte, MG, Brazil.
  • Nolasco F; Hospital das Clínicas, Universidade Federal de Minas Gerais, Alfa Institute of Gastroenterology, Belo Horizonte, MG, Brazil.
  • Bernardes AM; Hospital das Clínicas, Universidade Federal de Minas Gerais, Alfa Institute of Gastroenterology, Belo Horizonte, MG, Brazil.
  • Sanches SRA; Hospital das Clínicas, Universidade Federal de Minas Gerais, Alfa Institute of Gastroenterology, Belo Horizonte, MG, Brazil.
  • Savassi-Rocha PR; Hospital das Clínicas, Universidade Federal de Minas Gerais, Alfa Institute of Gastroenterology, Belo Horizonte, MG, Brazil.
Arq Bras Cir Dig ; 32(1): e1427, 2019 Feb 07.
Article em En, Pt | MEDLINE | ID: mdl-30758475
INTRODUCTION: Gastric gastrointestinal tumors (GIST) are a rare and usually asymptomatic neoplasm that can present as abdominal mass in more advanced scenarios. Since surgical resection is the main aspect of the treatment, locally advanced tumors require multivisceral resection and, therefore, higher postoperative morbidity and mortality. OBJECTIVE: To perform a review the literature on the topic, with emphasis on the neoadjuvant therapy. METHODS: Literature review on the Medline database using the following descriptors: gastrointestinal stromal tumors, neoadjuvant therapy, imatinib mesylate and molecular targeted therapy. RESULTS: Surgical resection remains the cornerstone for the treatment of GISTs; however, tyrosine kinase inhibitors have improved survival as an adjuvant therapy. More recently, neoadjuvant therapy have been described in the treatment of locally advanced tumors in order to avoid multivisceral resection. CONCLUSION: Despite surgical resection remains as the most important aspect of the treatment of GISTs, adjuvant and neoadjuvant therapy with tyrosine kinase inhibitors have shown to both improve survival and resectability, respectively.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Gástricas / Terapia Neoadjuvante / Tumores do Estroma Gastrointestinal / Mesilato de Imatinib / Antineoplásicos Limite: Humans Idioma: En / Pt Revista: Arq Bras Cir Dig Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Brasil País de publicação: Brasil

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Gástricas / Terapia Neoadjuvante / Tumores do Estroma Gastrointestinal / Mesilato de Imatinib / Antineoplásicos Limite: Humans Idioma: En / Pt Revista: Arq Bras Cir Dig Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Brasil País de publicação: Brasil